m+Medelevator.RU
← Поиск публикаций
JACC. Cardiovascular imaging · 2025

Guiding Automated Implementation Strategies for Patients With Atherosclerotic Plaque on Coronary Computed Tomographic Angiography: Rationale and Design of the Artificial Intelligence-DECIDE Study.

СтатьяПротокол клинического исследованияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Rinehart Sarah, Blankstein Ron, Januzzi James L, McCarthy Cian, Scherer Markus, O'Neal Wesley T, Mullen Sarah, Rogers Campbell, Shaw Leslee J, DECIDE Investigators

Аннотация

BACKGROUND: Approximately half of the patients with abnormal findings have no minimal changes in clinical management after stress testing.

OBJECTIVES: The primary aim of this study is to assess changes in preventive and anti-ischemic care for stable patients with atherosclerotic plaque on coronary computed tomographic angiography (CTA).

METHODS: Projected enrollment is 20,000 patients (∼40 sites) who underwent diagnostic testing for suspected or known coronary artery disease. Changes in medical therapy (dosing and type) and coronary revascularization will be collected through an automated electronic health record data extraction through 1 year of follow-up. In select subgroups, artificial intelligence-enabled quantitative measures of coronary atherosclerotic plaque (QCPA) will be provided promptly or delayed by 90 days, such that prompt decisions guided by coronary artery disease stenosis alone can be compared with QCPA-guided treatment.

RESULTS: A total of 6 care pathways will be evaluated: 1) no QCPA is provided (usual testing); 2) QCPA is provided but delayed and subsequently incorporated into a revised final report to guide patient management; 3) immediate QCPA is provided in nonrevascularized patients; 4) immediate QCPA is provided to patients with prior stenting in 1 vessel; 5) immediate QCPA is provided to asymptomatic patients referred for coronary CTA; and 6) patients referred to stress testing with no coronary CTA (ie, the comparator).

CONCLUSIONS: The DECIDE (DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management) study will enroll and characterize a broad spectrum of patients who require initiation and intensification of preventive care. The authors will use efficient and automated systems to evaluate the impact of quantitative atherosclerotic plaque measurement on preventive care that will help guide implementation strategies to improve outcomes for patients undergoing coronary CTA.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты